Скачать с ютуб Targeting Cancer Pathways: The Epigenetics Question в хорошем качестве

Targeting Cancer Pathways: The Epigenetics Question

Participating Experts: Stephen B. Baylin, MD (Johns Hopkins), Charles Roberts, MD PhD, (Dana Farber), Ali Shilatifard, PhD (Northwestern) ⬇️ Expand “Show More” to view abstract and table of contents ℹ️ Explore epigenetics pathway diagrams: https://cst-science.com/cli7eg Tumors are complex tissues in which the cancer cells evolve traits that promote their own survival and progression of the disease. Some of these traits involve epigenetic mechanisms to drive oncogenesis, stimulate tumor cell proliferation, and evasion of the immune system. This webinar explores how aberrant changes in epigenetic modification can affect the expression of key genes and contribute to the pathological progression of cancer. Topics include: • The major epigenetic changes seen in tumor tissue • How specific epigenetic pathways can be targeted for therapeutic intervention • The role of histone modifications (methylation, acetylation, ubiquitylation, phosphorylation, and others) in tumor survival and progression. Table of Contents 0:00 Welcome and overview 2:32 Stephen Baylin speaker profile 3:18 Epigenetics – classical and modern 4:52 Epigenomics hard drive and software 5:53 Cancer and the Epigenome 7:39 The position of mutations and the abnormal epigenome in tumor progression 8:51 The hallmarks of cancer and therapy targets 10:29 A trial of low dose epigenetic therapy for advanced NSCLC – what have we learned? 11:32 Images of patient with partial response: hepatic metastases 12:59 Potential for epigenetic Rx priming to immune tolerance therapy 14:11 Immune tolerance 14:54 Study design 16:19 Viral defense – nucleotide sensing 18:15 Hypothesis – epigenetic therapy sensitizing to immune checkpoint therapy 19:35 Charles Roberts speaker profile 20:27 SWI/SNF (BAF) chromatin remodeling complexes in cancer 21:34 Rhabdoid tumors 22:01 The SWI/SNF complex mobilizes nucleosomes 22:53 Snf5 targeted mice develop aggressive cancers 22:43 Frequent inactivating mutations of SWI/SNF complex subunitsd in a variety of cancers 24:54 Rhabdoid tumors have the lowest somatic mutation rate across cancers analyzed so far at the Broad (~3000 exomes) 25:51 Swi/Snf and polycomb: epigenetic antagonism? 26:36 Ezh2 is essential for in vivo tumor formation after Snf5 inactivation 27:33 Phase I trial: Complete response in a malignant rhabdoid tumor patient treated with and EZH2 inhibitor 29:02 Project Achilles: ARID1B is the #1 dependency in ARID1A mutant cancer cells 29:47 Residual SWI/SNF complexes can be a vulnerability in cancers containing a SWI/SNF subunit mutation 31:14 Conclusions 32:04 Ali Shilatifard speaker profile 33:31 Cancer prevalence with age 34:39 Enhancer malfunction in cancer 35:43 Stem cells and epigenetic processes in cancer pathogenesis 37:44 Chromosomal translocations in MLL and leukemogenesis? 40:13 Examples of acute leukemia 41:06 Model systems for study of MLL 42:23 Purification of yeast Set1/COMPASS family of H3K4 methylases 45:13 Cancer genes identified 46:38 Enhancer/promoter looping in transcriptional activation 47:39 Enhancer malfunction in upregulated activation of oncogene expression 48:49 Question and answer About CST®: Cell Signaling Technology (CST) is a private, family-owned company, founded by scientists and dedicated to providing high-quality research tools to the biomedical research community. Our employees operate worldwide from our U.S. headquarters in Massachusetts, and our offices in the Netherlands, China, and Japan. https://cellsignal.com/about All trademarks are the property of their respective owners. For the most up-to-date trademark information, please visit https://www.cellsignal.com/trademarks #Antibody #CSTWebinar